Select Page
ken oliver

KENNETH J. OLIVIER JR., PHD, DRUG DEVELOPMENT EXPERT

Kenneth J. Olivier Jr., PhD, has been developing drugs for over 18 years and is currently serving as Vice President of Development at TScan Therapeutics, Inc., Head of Toxicology and various operations at Orange Grove Bio, as well as President of Olivier KOnsulting since inception on 02SEP2015. He is also an Instructor for Biotech Primer teaching customized drug discovery, development and commercialization courses to biotechnology and pharmaceutical industry professionals, as well as academic scholars at highly distinguished institutions, including Dana Farber Cancer Institute and Harrington Discovery Institute. Dr. Olivier’s work experience includes biotechnology and pharmaceutical companies, spending time at Regeneron, Biogen, GlaxoSmithKline, Merrimack Pharmaceuticals, Acceleron Pharma, Torque Therapeutics, Morphic Therapeutic developing small molecule drugs, biologics, diagnostics, antibody drug conjugates, antibody directed nanotherapies, gene (AAV, LV vectors) and cell based therapies (TAA and TCR) for indications in cardiology, neurology, metabolic disease, neuromuscular disease, immunology, rare disease, infectious disease, fibrosis and oncology. Though his primary duties have been safety evaluations, Dr. Olivier has held the role of project leader, head of project management, head of regulatory, head of pharmacokinetics, head of bioanalytical development, validation and sample analysis and head of nonclinical supporting multiple INDs, IMPDs, CTAs, NDAs, BLAs, PLEs and IDEs. In addition, Dr. Olivier is an adjunct faculty member at Oklahoma State University and has taught drug development courses at Harvard, MIT and through the American College of Toxicology, for which he is currently serving on the Editorial Board (International Journal of Toxicology) and formerly as an elected Council Member.  In addition to teaching and developing much needed diagnostics/devices/therapies, Dr. Olivier enjoys participating on Scientific Advisory Boards, including a DARPA funded project at MIT and a start-up company in San Francisco. Dr. Olivier’s publications include evaluations of toxicity related to novel therapeutics in immunology and oncology, such as interferons, bispecific antibodies, targeted liposomal nanotherapies and Cytokine trap technology. Dr. Olivier obtained a BS in Toxicology from the University of Louisiana at Monroe and a PhD in Veterinary Biomedical Sciences from Oklahoma State University.